Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

I am retiring from the Italian National Health Service. If someone were to ask me what I think of the Italian National Health ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...